Eli Lilly and Company $LLY Stake Raised by RVW Wealth LLC

RVW Wealth LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 93.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,187 shares of the company’s stock after buying an additional 2,027 shares during the quarter. RVW Wealth LLC’s holdings in Eli Lilly and Company were worth $4,845,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $30,000. Maseco LLP increased its position in Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $39,000. Finally, Aventus Investment Advisors Inc. raised its stake in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after purchasing an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.3%

NYSE LLY traded up $14.49 during trading hours on Tuesday, hitting $1,157.61. 2,130,131 shares of the company’s stock were exchanged, compared to its average volume of 2,977,802. The business’s 50 day moving average is $1,175.28 and its 200-day moving average is $1,090.99. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 12-month low of $783.85 and a 12-month high of $1,292.65. The firm has a market capitalization of $1.09 trillion, a P/E ratio of 38.85, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the previous year, the business earned $6.31 EPS. The firm’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Royal Bank Of Canada upped their target price on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a report on Wednesday, July 8th. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 23rd. HSBC boosted their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Finally, Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,311.96.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded approval of Jaypirca for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma patients without a 17p deletion. The decision, supported by Phase 3 data, could expand the drug’s addressable market and strengthen Lilly’s oncology growth. FDA expands Eli Lilly’s blood cancer drug label
• Positive Sentiment: Lilly’s experimental cancer drug olomorasib received FDA orphan-drug designation for pancreatic cancer. The status may provide development incentives and potential market exclusivity, reinforcing Lilly’s strategy to diversify beyond GLP-1 medicines. Lilly expands oncology footprint
• Positive Sentiment: New analysis presented at the European Association for the Study of Diabetes meeting showed Lilly’s oral GLP-1 candidate Foundayo produced greater weight loss and better blood-sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. If confirmed in later-stage studies and commercialized successfully, the pill could extend Lilly’s metabolic-health leadership. Foundayo analysis versus oral semaglutide
• Positive Sentiment: Lilly expanded its collaboration with Gate Bioscience in a potential agreement worth more than $870 million, while also making its insitro-developed machine-learning models available through Lilly TuneLab. These deals could improve future drug discovery and add longer-term pipeline value. Lilly expands Gate Bioscience collaboration
• Neutral Sentiment: Early-stage updates for Lilly’s elt­re­kibart antibody and a new basal-insulin candidate indicate continued pipeline progress, but Phase 1 results do not yet establish commercial viability. Lilly also plans 21 dermatology presentations, potentially providing additional catalysts later this month.
• Negative Sentiment: Analysts and commentators cautioned that LLY’s valuation—roughly 38 times earnings, well above the broader market—already reflects very high growth expectations. Any slowdown in Zepbound or Mounjaro demand, pricing pressure, trial setbacks or regulatory delays could leave limited room for error. Eli Lilly valuation risk

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.